Caroline Dartigeas

3.7k total citations
47 papers, 1.3k citations indexed

About

Caroline Dartigeas is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Caroline Dartigeas has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Genetics, 23 papers in Pathology and Forensic Medicine and 14 papers in Hematology. Recurrent topics in Caroline Dartigeas's work include Chronic Lymphocytic Leukemia Research (31 papers), Lymphoma Diagnosis and Treatment (23 papers) and Acute Myeloid Leukemia Research (11 papers). Caroline Dartigeas is often cited by papers focused on Chronic Lymphocytic Leukemia Research (31 papers), Lymphoma Diagnosis and Treatment (23 papers) and Acute Myeloid Leukemia Research (11 papers). Caroline Dartigeas collaborates with scholars based in France, Italy and United States. Caroline Dartigeas's co-authors include Marco Montillo, John Catalano, Philippe Solal‐Céligny, Christian H. Geisler, Anna Dmoszyńska, B. V. Аfanasiev, Moiseev Si, Peter Ganly, Loree Larratt and Krzysztof Warzocha and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Caroline Dartigeas

44 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline Dartigeas France	13	836	736	327	320	318	47	1.3k
Loïc Ysebaert France	15	914 1.1×	783 1.1×	430 1.3×	308 1.0×	445 1.4×	57	1.4k
Georg Hopfinger Austria	22	984 1.2×	987 1.3×	390 1.2×	533 1.7×	458 1.4×	58	1.8k
Brigitte Dreyfus France	10	887 1.1×	705 1.0×	240 0.7×	121 0.4×	398 1.3×	37	1.1k
Andrew R. Rezvani United States	20	392 0.5×	361 0.5×	862 2.6×	527 1.6×	413 1.3×	72	1.6k
Jeanette Lundin Sweden	21	1.1k 1.3×	1.1k 1.6×	448 1.4×	544 1.7×	1.1k 3.3×	53	2.2k
Iwona Hus Poland	18	451 0.5×	239 0.3×	239 0.7×	458 1.4×	710 2.2×	96	1.2k
Benoît Tessoulin France	18	244 0.3×	306 0.4×	365 1.1×	516 1.6×	219 0.7×	79	1.2k
MF Martelli Italy	15	214 0.3×	544 0.7×	405 1.2×	376 1.2×	506 1.6×	30	1.2k
Nadine Morineau France	16	426 0.5×	370 0.5×	821 2.5×	591 1.8×	102 0.3×	37	1.5k
Mariagrazia Michieli Italy	24	376 0.4×	553 0.8×	599 1.8×	1.2k 3.7×	162 0.5×	107	1.9k

Countries citing papers authored by Caroline Dartigeas

Since Specialization

Citations

This map shows the geographic impact of Caroline Dartigeas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Dartigeas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Dartigeas more than expected).

Fields of papers citing papers by Caroline Dartigeas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Dartigeas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Dartigeas. The network helps show where Caroline Dartigeas may publish in the future.

Co-authorship network of co-authors of Caroline Dartigeas

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Dartigeas. A scholar is included among the top collaborators of Caroline Dartigeas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Dartigeas. Caroline Dartigeas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nguyen‐Khac, Florence, Marine Baron, Romain Guièze, et al.. (2024). Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study). British Journal of Haematology. 205(2). 495–502. 2 indexed citations

Hueso, Thomas, Thomas Gastinne, Catherine Thiéblemont, et al.. (2022). Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. Bone Marrow Transplantation. 57(4). 627–632. 3 indexed citations

Dartigeas, Caroline, et al.. (2022). FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL. SHILAP Revista de lepidopterología. 4(3). 65–74. 6 indexed citations

Leblond, Véronique, Cécile Tomowiak, Kamel Laribi, et al.. (2022). Maladie de Waldenström : actualités et perspectives en 2022. Bulletin du Cancer. 110(1). 88–100. 1 indexed citations

Dartigeas, Caroline, Loïc Ysebaert, Pierre Feugier, et al.. (2022). Overall and Subgroup Results from the Third Interim Analysis of FIRE, a Real-World Study of Ibrutinib Treatment for CLL/SLL in France. Blood. 140(Supplement 1). 9906–9907.

Marlet, Julien, Philippe Gatault, Hélène Longuet, et al.. (2021). Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia. Vaccines. 9(10). 1055–1055. 29 indexed citations

Jurczak, Wojciech, Caroline Dartigeas, Marta Coscia, et al.. (2021). BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). Blood. 138(Supplement 1). 3732–3732. 2 indexed citations

Ghez, David, Caroline Protin, Marine Baron, et al.. (2018). Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 131(17). 1955–1959. 205 indexed citations

Leblond, Véronique, Melih Aktan, Caroline Dartigeas, et al.. (2018). Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 103(11). 1889–1898. 13 indexed citations

10.

Aubin, F., Éric Toussirot, Francine Garnache‐Ottou, et al.. (2015). New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Experimental Hematology and Oncology. 5(1). 10–10. 17 indexed citations

11.

Leprêtre, Stéphane, Caroline Dartigeas, Hervé Maisonneuve, et al.. (2014). Results of a Phase II Randomizing Intensified Rituximab Pre-Phase Followed By Standard FCR Vs Standard FCR in Previously Untreated Patients with Active B-Chronic Lymphocytic Leukemia (B-CLL). CLL2010FMP (for fit medically patients): A Study of the french Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS). Blood. 124(21). 3329–3329. 2 indexed citations

12.

Arbion, Flavie, Caroline Dartigeas, Martine Delain, et al.. (2013). Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years’ experience in a single centre. Annals of Hematology. 93(1). 147–156. 4 indexed citations

13.

Bally, Cécile, Sylvain Thépot, Bruno Quesnel, et al.. (2013). Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leukemia Research. 37(6). 637–640. 44 indexed citations

14.

Rousselot, Philippe, Luigina Mollica, Gabriel Étienne, et al.. (2012). Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial. Blood. 120(21). 3770–3770. 14 indexed citations

15.

Désoubeaux, Guillaume, Charline Caumont, Christophe Passot, et al.. (2011). Two cases of opportunistic parasite infections in patients receiving alemtuzumab. Journal of Clinical Pathology. 65(1). 92–95. 9 indexed citations

16.

Neste, Eric Van Den, Rémi Letestu, Thérèse Aurran‐Schleinitz, et al.. (2011). Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & lymphoma. 53(3). 362–370. 4 indexed citations

17.

Robak, Tadeusz, Anna Dmoszyńska, Philippe Solal‐Céligny, et al.. (2010). Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 28(10). 1756–1765. 358 indexed citations

18.

Guièze, Romain, Anne Jouinot, Raphaël Itzykson, et al.. (2010). Azacytidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell Transplantation (allo-HSCT): Results of the French ATU Program.. Blood. 116(21). 1293–1293. 3 indexed citations

19.

Salles, Gilles, Nicolas Mounier, Sophie de Guibert, et al.. (2008). Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 112(13). 4824–4831. 239 indexed citations

20.

Mahéo, Karine, et al.. (2005). Differential sensitization of cancer cells to doxorubicin by DHA: A role for lipoperoxidation. Free Radical Biology and Medicine. 39(6). 742–751. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact